Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
August 12, 2024 8:07 AM EDTEsoGuard® test volume increased 31 percent quarterly; 44 percent annually
Clinical data now well-positioned for final push towards broad coverage and reimbursement
Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment
Conference call and webcast to be held today, August 12th at 8:30 AM EDT
NEW YORK, Aug. 12, 2024 /PRNewswire/... More
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
August 8, 2024 8:31 AM EDTEvent held at Fort Worth Fire Department in partnership with Front Line Mobile Health
NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of... More
